Vivos Receives FDA IDE Approval for RadioGel Trial
KENNEWICK, Wash., July 6, 2026 Vivos Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
KENNEWICK, Wash., July 6, 2026 Vivos Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the...
KENNEWICK, Wash., June 5, 2026 Vivos Inc. announced the submission of an Early Feasibility Investigational Device Exemption (IDE) application...
